POLBF (Poolbeg Pharma) FCF Margin %: 0.00% (As of Dec. 2025)


What is Poolbeg Pharma FCF Margin %?

Poolbeg Pharma POLBF -20.36% FCF Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Poolbeg Pharma ranks worse than 104275.18% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Poolbeg Pharma's Free Cash Flow for the six months ended in Dec. 2025 was $-3.18 Mil. Poolbeg Pharma's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Poolbeg Pharma's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Poolbeg Pharma's current FCF Yield % is -9.03%.

The historical rank and industry rank for Poolbeg Pharma's FCF Margin % or its related term are showing as below:


POLBF's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -84.65
* Ranked among companies with meaningful FCF Margin % only.

Poolbeg Pharma FCF Margin % Related Terms

Poolbeg Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma FCF Margin % Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 0.00 0.00 0.00

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

POLBF vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Poolbeg Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poolbeg Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Poolbeg Pharma's FCF Margin % falls into.


Poolbeg Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Poolbeg Pharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-6.48/0
= %

Poolbeg Pharma's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-3.18/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Poolbeg Pharma (POLBF) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poolbeg Pharma and its competitors. According to the industry distribution chart, Poolbeg Pharma ranks #999999 out of 959 companies in the Biotechnology industry.
Is Poolbeg Pharma's FCF Margin % too high?
Poolbeg Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Poolbeg Pharma ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Poolbeg Pharma's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #999999 out of 959 companies for FCF Margin %. This places Poolbeg Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Poolbeg Pharma and its competitors. Poolbeg Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.